The role of idiotype vaccines in the treatment of human B-cell malignancies.
Twelve years after the first formal demonstration that it is possible to vaccinate a cancer patient against an antigen derived from his/her own tumor, idiotype vaccines are now well into Phase III clinical trials for the treatment of follicular lymphoma. Meanwhile, their potential has also begun to be explored in other non-Hodgkin's lymphoma settings, such as that of mantle cell lymphoma. Another well known field of potential application for idiotype vaccines is that of multiple myeloma. However, the currently available results, even with the advent of dendritic cells, seem to be less promising than those obtained in lymphoma, to such an extent that idiotype vaccines are currently tested in multiple myeloma patients in the context of more aggressive therapeutic strategies.
Bendandi
Maurizio
M
Department of Hematology and Cell Therapy Area, University Clinic of Navarre - Center for Applied Medical Research, Avda. Pio XII, 36 31008 Pamplona (Navarre), Spain. mbendandi@unav.es
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D020566:Dendritic Cells, Follicular / Q000276:immunology; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000517:prevention & control; D008224:Lymphoma, Follicular / Q000276:immunology / Q000517:prevention & control; D020522:Lymphoma, Mantle-Cell / Q000276:immunology / Q000517:prevention & control; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000517:prevention & control*; D009101:Multiple Myeloma / Q000276:immunology / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes; D019444:Vaccines, DNA